AGC
ORIAU

Angelo Gordon & Co’s Orion Biotech Opportunities Corp. Units ORIAU Stock Holding History

Angelo Gordon & Co’s Portfolio ORIAU Stock Details ORIAU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-300,000
Closed -$3.02M – 254
2021
Q2 		$3.02M Buy
+300,000
New +$3.02M 0.15% 48

Other funds holding ORIAU

JP
JNE Partners London, United Kingdom $243M AUM 2.37% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $244M AUM 110.95% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Angelo Gordon & Co's ORIAU Position: Q3 2021 in Review

Angelo Gordon & Co sold out of Orion Biotech Opportunities Corp. Units (ORIAU) in Q3 2021, closing a stake of 300,000 shares — an estimated $3.02M sold.

Angelo Gordon & Co first reported a position in ORIAU in Q2 2021 and held it in 1 quarter. The position peaked at $3.02M in Q2 2021. 21 funds tracked by Wall St. Rank hold ORIAU as of Q3 2021.

  • Angelo Gordon & Co reported no remaining Orion Biotech Opportunities Corp. Units position as of Q3 2021 after selling out during the quarter.
  • Angelo Gordon & Co sold 300,000 Orion Biotech Opportunities Corp. Units shares in Q3 2021, an estimated $3.02M.
  • Angelo Gordon & Co first reported a position in Orion Biotech Opportunities Corp. Units in Q2 2021 and held it in 1 quarter.
  • Angelo Gordon & Co's Orion Biotech Opportunities Corp. Units position peaked at $3.02M in Q2 2021.
  • 21 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Units as of Q3 2021.

Based on Angelo Gordon & Co's 13F filing for Q3 2021, filed 15 Nov 2021.